A new development in the case over Eli Lilly and Company’s patent on its drug Strattera which treats ADHD. Last year, a district court ruled that Eli Lilly’s patent on its drug Strattera is invalid, opening the market up to cheaper generic copies of Strattera, but this week, a U.S. Court of Appeals has upheld Eli Lilly’s patent on the ADHD drug, which means that low-cost, affordable generic versions of Strattera won’t be hitting the market until at least 2017.
ADHD is a neurobehavioral developmental disorder, primarily characterized by attention problems and hyperactivity. Symptons of ADHD usually begin presenting starting before seven years of age and the condition is considered chronic. According to data from the Centers for Disease Control, 4.5 million children in the U.S. have been diagnosed with ADHD.
It’s a big blow to generic pharmaceutical companies which have been working on generic versions of Strattera for years. At least 7 of the 10 generic-drug makers involved in the case already have tentative U.S. Food and Drug Administration approval to sell generic versions of Strattera, but now the release of those generic counterparts will be on hold until at least 2017 when the key Strattera patent is now due to expire. Teva, Mylan and other generic drug manufacturers had filed the legal challenge to Lilly’s patent for Strattera
Considering a thirty-day supply of brand-name Strattera is currently running about $175, the release of generic counterparts would easily have meant huge savings for the families of many ADHD patients.
“We are pleased with today’s ruling from the Court of Appeals regarding Strattera’s method-of-use patent and remain confident that the patent is valid and enforceable,” said Robert A. Armitage, senior vice president and general counsel for Lilly.
Do you use Strattera for ADHD? Tell us about it!
- Generic Drug Alert: Patent on Strattera Ruled Invalid, Generic Versions Of Strattera to Hit the Market
- Judge Blocks Release of Generic Versions of Lilly’s Strattera Drug for ADHD
- Generic Drug Alert: FDA Will Not Extend Patent on Treximet Migraine Drug, Is a Cheaper Generic On the Way?
- Thought Viagra Was Going Generic Next Year? Pfizer Fights to Keep Its Patent Until 2019
- Huge Generic Drug News! FDA Grants Tentative Approval for Generic Version of Cholesterol Drug Crestor